MedTrace Logo

Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions

NCT04407000 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-08-11

No results posted yet for this study

Summary

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

Conditions

  • Bioequivalence

Interventions

DRUG

Test: Favipiravir 200 mg (LOQULAR)

Test Drug

DRUG

Reference: Favipiravir 200 mg (Avigan)

Reference Drug

Sponsors & Collaborators

  • Novagenix Bioanalytical Drug R&D Center

    collaborator NETWORK

  • Farmagen Ar-Ge Biyot. Ltd. Sti

    collaborator NETWORK

  • World Medicine ILAC SAN. ve TIC. A.S.

    lead INDUSTRY

Principal Investigators

  • Muradiye Nacak, MD,PhD · Farmagen Ar-Ge Biyot. Ltd. Sti

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2020-07-20
Completion
2020-08-08

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407000 on ClinicalTrials.gov